The TITAN study: a plain language summary looking at how PSA decline with apalutamide therapy is associated with longer survival and improved outcomes in people with metastatic prostate cancer
This Plain Language Summary of Publication article from Future Oncology discusses the results of an additional analysis of the TITAN study. The TITAN study looked at whether the medication, apualutamide, could be used to treat people with metastatic castration-sensitive prostate cancer.
Visit the Future Medicine using the link to read the article.
The original article on which this summary is based is called ‘Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer’ and was published in Annals of Oncology.
Visit Nature using the link to read the article.